$KZIA Income Statement | Understand Stock

$KZIA

$8.17 +$0.30 (3.81%) Close

Financial Statements

In millions of AUD, except per-share amounts

	FY2025 12 months to Jun 30, 2025	FY2024 12 months to Jun 30, 2024	FY2023 12 months to Jun 30, 2023	FY2022 12 months to Jun 30, 2022	FY2021 12 months to Jun 30, 2021
Revenue
Other income
Finance income
Expenses
Research and development expense
General and administrative expense
Fair value losses on financial assets at fair value through profit or loss
Loss on revaluation of contingent consideration
Impairment of intangible assets
(Loss) gain on remeasurement of other financial liabilities
Gain on remeasurement of promissory note
Gain on remeasurement of contingent consideration
Commercialisation
Loss before income tax benefit

Income tax benefit
Loss after income tax benefit
Owners of Kazia Therapeutics Limited
Other comprehensive income/(loss)
Items that may be reclassified subsequently to profit or loss
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax
Other comprehensive income (loss), net of tax
Total comprehensive income/(loss)
Basic earnings per share
Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited
Basic earnings per share
Diluted earnings per share

Comments